Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction

NCT02246595 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Sepsis
Septic Shock

Interventions

BIOLOGICAL: CaCP29
BIOLOGICAL: Placebo

Sponsor

InflaRx GmbH